Phio Pharma Takes RXi’s Self-Delivering RNAi Technology, Refocuses On Immuno-Oncology
Executive Summary
RXi thought it had solved the RNAi delivery issue but was focused on dermatology and ophthalmology. New CEO Dispersyn thought the platform offered more lucrative promise as a way of optimizing IO therapy.
You may also be interested in...
RXi Thinks Self-Delivering RNAi Could Be The Ticket In A Tricky Field
Biotech's asymmetrical, shorter RNAi therapeutics are water-soluble and therefore can be self-delivering. Lead candidate RXI-109 is being studied in both hypertrophic and retinal scarring, but the firm has new funding that could help it move into oncology.
Disc Sees Promise In Hematology With Former Roche Schizophrenia Candidate
Phase II data in two rare hematological disorders show potential for transformative therapeutic benefit, according to analysts. The company awaits more results for further confirmation.
Next-Gen Gene Therapy Firm Kate Therapeutics Starts Out With Big Pharma Partner
Kate is focused on delivering gene therapies for two rare, neuromuscular diseases by deploying AAV technology that it says will target muscle tissue and enable regulated therapeutic payloads.